Medscape2d
‘Take a Photograph’: Trial Shows Big Survival Gain in Advanced EGFR-Mutant NSCLC
Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...
Healio3d
First-line combination should be ‘new standard’ in advanced lung cancer
The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...
Yahoo Finance4d
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
together reinforce osimertinib as an effective, safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice ...
National Institute for Health and Care Excellence1mon
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
ascopubs.org1mon
Osimertinib Plus Antiangiogenic Agents: A Promising New Paradigm With Uncertain Results
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Morningstar4d
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated ...
AstraZeneca: New study results reinforce TAGRISSO (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
In LAURA Phase III trial, TAGRISSO continues to demonstrate improved overall survival trend in unresectable, Stage III setting SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib ...